

UNIVERSITI TEKNOLOGI MARA

**MECHANISMS OF RANIBIZUMAB
AS AN ANTI-SCARRING AGENT IN
TRABECULECTOMY**

SITI MUNIRAH MD NOH

PhD

September 2017

AUTHOR'S DECLARATION

I declare that the work in this thesis was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the results of my own work, unless otherwise indicated or acknowledged as referenced work. This topic has not been submitted to any other academic institution or non-academic institution for any degree or qualification.

I hereby acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name of Student	:	Siti Munirah Bt Md Noh
Student I.D. No.	:	2011220586
Programme	:	Doctor of Philosophy (Medicine) – MD 990
Faculty	:	Medicine
Thesis Title	:	Mechanisms Of Ranibizumab As An Anti- Scarring Agent In Trabeculectomy
Signature of Student	:	
Date	:	September 2017

ABSTRACT

Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient's eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon's fibroblast (HTF) leads to significant cases of surgical failure. Anti-vascular endothelial growth factor (VEGF) has become the focus in current scar modulation strategy. Improved bleb morphology following trabeculectomy augmented with ranibizumab has been reported. However, mechanism of actions of ranibizumab on HTF is not well understood. Therefore, this *in vitro* study was conducted to elucidate mechanism of actions of ranibizumab on HTF. HTF used in this study were propagated from Tenon's capsule obtained from patients undergoing trabeculectomy. Firstly, isolated and characterized HTF were treated with different concentrations of ranibizumab in serum and serum-free media for 24 and 48 hours and then HTF viability was measured using MTT assay. Then, HTF were extracted to measure the expression of collagen Type 1 (COL1A1), fibronectin (FN), transforming growth factor- β 1 and - β 2 (TGF- β 1 & TGF- β 2) using qRT-PCR and ELISA. The experiment was followed with metabolomics profiling which was performed to identify the most significant metabolite regulated by ranibizumab. Finally, the expression of regulatory genes and proteins involved in the cell cycle regulation and angiogenesis including p21, p53, CDK2, CDK4, *PTEN*, *AKT1* and *THBS1* were measured by RT² Profiler PCR Array and Western Blot. Findings from the MTT assay showed that ranibizumab at the concentration of 0.5 mg/ml induce significant reduction in HTFs viability. The optimum degree of reduction was observed in serum-free media incubated for 48 hours. Furthermore, results suggested that ranibizumab mediates the down-regulation of COL1A1 and TGF- β 1 at gene level, but not at the protein level. No relevant changes were observed in FN and TGF- β 2 mRNA level, but the proteins level was up-regulated. In metabolomics study, ranibizumab was shown to induce significant reduction in spermidine level. Therefore in subsequent experiment, ranibizumab effects were compared to DFMO, a potent irreversible inhibitor in spermidine synthesis. Findings show that ranibizumab exerts similar mechanism to DFMO in regulating spermidine expression by HTF, where it reduces *PTEN*, *AKT1* and *THBS1* expression. Moreover, ranibizumab administration increase p53 and p21 expression and reduces CDK2 and CDK4 expression. These observations suggest that ranibizumab might exert its anti-scarring property by enhancing the activities of p53 and p21, thus lead to reduction in CDK2 and CDK4. This shows that cell cycle of ranibizumab-treated HTF could be arrested, particularly at G1 phase.

ACKNOWLEDGEMENT

In the name of Allah, Ar-Rahman (the Most Compassionate) and Ar-Rahim (the Most Merciful). First and foremost, Alhamdulillah, all praise to Allah, the Almighty, for giving me the willpower to do the best throughout my doctoral journey. I am truly blessed to have Assoc. Prof. Dr. Sushil Kumar Vasudevan as my supervisor. There are not enough thanks for me to give to you for all your support, guidance, patience, and encouragement. You always have the time to listen to all my problems, either on work or personal life, no matter how big or small they are. Thank you, Dr. Sushil, for believing in me and kept pushing me to strive for the best. I want to thank my co-supervisors Dr. Siti Hamimah Sheikh Abdul Kadir for giving me valuable insights in the molecular works. I am also indebted to my friends and Ophthalmology colleagues, who gave me their time, encouragement and ideas when my thoughts were unfocused. Thanks to IMMB staffs for their support and laboratory works. Thanks also to those who support my expenses during my PhD; Ministry of Science, Technology and Innovation (MOSTI) for the E-Science grant (100-RMI/SF/6/2) and Ministry of Higher Education for RAGS grant (600-RMI/RAGS (88/2013). Last but not least, I want to express my full gratitude to my loving and caring family; this thesis is dedicated to all of you. Thanks to my father, Hj Md Noh Ideris, and mother, , for giving me constant love and assisting me throughout my life. Huge thanks to my other half, Nik Saiful Nizam, for your unswerving support, love and faith in me. Thank you for lending me your hand in raising our children when I am occupied with my research. To my beloved children; Nik Alya Husna and Nik Aliff Hakimi, may my works and efforts motivate all of you to gain success in this world and the hereafter.

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR'S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENT	v
TABLE OF CONTENTS	vi
LIST OF TABLES	xiv
LIST OF FIGURES	xv
LIST OF ABBREVIATIONS	xviii
CHAPTER ONE: INTRODUCTION	1
1.1 Background Of Study	1
1.2 Problem Statement	4
1.3 Hypothesis	5
1.4 Scope Of Study	5
1.5 Research Objectives	5
CHAPTER TWO: LITERATURE REVIEW	7
2.1 Glaucoma	7
2.2 Classification Of Glaucoma	8
2.2.1 Open Angle Glaucoma	8
2.2.1.1 Primary Open Angle Glaucoma	10
2.2.1.2 Secondary Open Angle Glaucoma	10
2.2.2 Angle Closure Glaucoma	11
2.2.2.1 Primary Angle Closure Glaucoma (PACG)	12
2.2.2.2 Secondary Angle Closure Glaucoma	13
2.3 Aqueous Humor	13
2.3.1 Aqueous Humor: An Overview	13
2.3.2 Aqueous Humor Production	15